Interpreting resistance data for HIV-1 therapy management--know the limitations

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Antiviral drug resistance is a key factor in HIV-1 therapy failure.
• Antiviral resistance testing has demonstrated benefits for subsequent treatment regimens.
• Genotypic and phenotypic assays have improved but still have limitations in fully characterizing resistance.

Purpose of the Study:

• To evaluate the role and interpretation of antiviral resistance testing in HIV-1 therapy.
• To explore the complementary information provided by genotypic and phenotypic assays.
• To address the challenge of translating in vitro resistance data into clinical practice.

Main Methods:

• Review of studies on genotypic and phenotypic antiviral resistance assays for HIV-1.
• Analysis of bioinformatics approaches for interpreting phenotypic resistance data (fold-resistance values, clinical response data).
• Examination of genotypic drug-resistance interpretation systems and their continuous updates.

Main Results:

• Both genotypic and phenotypic assays provide valuable, often complementary, information on HIV-1 drug resistance.
• Significant challenges persist in accurately interpreting in vitro resistance results for clinical implementation.
• Ongoing bioinformatics analyses and interpretation systems aim to establish clinical cut-offs and predict therapy outcomes.

Conclusions:

• Interpreting genotypic and phenotypic resistance data for clinical use remains a critical challenge in HIV-1 management.
• While assays have advanced, their full potential in guiding therapy is limited by interpretation complexities.
• Future prospective trials comparing different interpretation systems are needed but face design difficulties due to rapid scientific evolution.